Chronic Hepatitis C
Conditions
Brief summary
A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability，Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects
Detailed description
A total of 24 evaluable patients will be enrolled in this study. The study randomly divided into three dose groups and HEC110114 tablets planned dose levels are 600, 800, and 1200 mg, sofosbuvir tablets planned dose levels are 400 mg .
Interventions
DRUGHEC110114 Tablet
administered orally once daily
DRUGSofosbuvir Tablet
administered orally once daily
Sponsors
Sunshine Lake Pharma Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions; * Be able to complete the study according to the trail protocol; * Subjects (including partners) have no pregnancy plan within six months after the last dose of study drug and voluntarily take effective contraceptive measures; * Male subjects and must be 18 to 65 years of age inclusive; * Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive, and a body weight ≥50 kg for males and ≥45 kg for females; * No previous treatment with any direct-acting antiviral (DAA) drugs for HCV, such as Simeprevir, Sofosbuvir, Daclatasvir etc; * HCV RNA ≥10\*5 IU/mL at screening (Roche COBAS Taqman); * Chronic genotype 1-6 HCV Infection, multiple genotypes, subtype unidentifiable or others ; * Serum ALT ≤5 times ULN.
Exclusion criteria
* Allergies constitution ( multiple drug and food allergies); * History of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits or 100 mL of wine); * Donation or loss of blood over 450 mL within 3 months prior to screening; * History of any non-HCV liver diseases, including but not limited to hemochromatosis, primary biliary cirrhosis, Wilson's disease, autoimmune hepatitis, drug or alcoholic hepatitis, non-alcoholic steatohepatitis, etc; * 12-lead ECG with clinically significant; * Pregnant or lactating women; * Creatinine clearance \< 60 mL/min; * Subjects deemed unsuitable by the investigator for any other reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | From Days 1-10 | Incidence of adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | At pre-defined intervals from Days 1-7 | Maximum Observed Plasma Concentration |
| Tmax | At pre-defined intervals from Days 1-7 | Time to Maximum Observed Plasma Concentration |
| T1/2 T1/2 T1/2 T1/2 | At pre-defined intervals from Days 1-7 | Apparent Half-Life |
| AUClast | At pre-defined intervals from Days 1-7 | Area Under the Plasma Concentration vs Time Curve to Last Measurable Concentration |
| HCV RNA | At pre-defined intervals from Days 1-10 | HCV RNA declined from baseline |
Countries
China
Outcome results
None listed